These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 21147840)

  • 21. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.
    Gradilone SA; Masyuk TV; Huang BQ; Banales JM; Lehmann GL; Radtke BN; Stroope A; Masyuk AI; Splinter PL; LaRusso NF
    Gastroenterology; 2010 Jul; 139(1):304-14.e2. PubMed ID: 20399209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A human multi-lineage hepatic organoid model for liver fibrosis.
    Guan Y; Enejder A; Wang M; Fang Z; Cui L; Chen SY; Wang J; Tan Y; Wu M; Chen X; Johansson PK; Osman I; Kunimoto K; Russo P; Heilshorn SC; Peltz G
    Nat Commun; 2021 Oct; 12(1):6138. PubMed ID: 34686668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Murine autosomal recessive polycystic kidney disease with multiorgan involvement induced by the cpk gene.
    Gattone VH; MacNaughton KA; Kraybill AL
    Anat Rec; 1996 Jul; 245(3):488-99. PubMed ID: 8800407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis.
    Suzuki S; Mori Y; Nagano A; Naiki-Ito A; Kato H; Nagayasu Y; Kobayashi M; Kuno T; Takahashi S
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27973395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).
    Banales JM; Masyuk TV; Gradilone SA; Masyuk AI; Medina JF; LaRusso NF
    Hepatology; 2009 Jan; 49(1):160-74. PubMed ID: 19065671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant expression of laminin-332 promotes cell proliferation and cyst growth in ARPKD.
    Vijayakumar S; Dang S; Marinkovich MP; Lazarova Z; Yoder B; Torres VE; Wallace DP
    Am J Physiol Renal Physiol; 2014 Mar; 306(6):F640-54. PubMed ID: 24370592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal dysfunction but not cystic change is ameliorated by neonatal epidermal growth factor in bpk mice.
    Nakanishi K; Gattone VH; Sweeney WE; Avner ED
    Pediatr Nephrol; 2001 Jan; 16(1):45-50. PubMed ID: 11198603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peroxisome proliferator-activated receptor gamma agonist as a novel treatment for interstitial cystitis: A rat model.
    Mahal A; Young-Lin N; Dobberfuhl A; Estes J; Comiter CV
    Investig Clin Urol; 2018 Jul; 59(4):257-262. PubMed ID: 29984341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.
    Buchholz B; Klanke B; Schley G; Bollag G; Tsai J; Kroening S; Yoshihara D; Wallace DP; Kraenzlin B; Gretz N; Hirth P; Eckardt KU; Bernhardt WM
    Nephrol Dial Transplant; 2011 Nov; 26(11):3458-65. PubMed ID: 21804086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Congenital hepatic fibrosis in autosomal recessive polycystic kidney disease.
    Wen J
    Clin Transl Sci; 2011 Dec; 4(6):460-5. PubMed ID: 22212229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease.
    Kugita M; Nishii K; Yamaguchi T; Suzuki A; Yuzawa Y; Horie S; Higashihara E; Nagao S
    PLoS One; 2017; 12(5):e0177934. PubMed ID: 28542433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory effects of peroxisome proliferator-activated receptor γ agonists on collagen IV production in podocytes.
    Li Y; Shen Y; Li M; Su D; Xu W; Liang X; Li R
    Mol Cell Biochem; 2015 Jul; 405(1-2):233-41. PubMed ID: 25920446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension.
    Sakamoto A; Hongo M; Saito K; Nagai R; Ishizaka N
    Eur J Pharmacol; 2012 May; 682(1-3):131-6. PubMed ID: 22387860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for a "Pathogenic Triumvirate" in Congenital Hepatic Fibrosis in Autosomal Recessive Polycystic Kidney Disease.
    Jiang L; Fang P; Weemhoff JL; Apte U; Pritchard MT
    Biomed Res Int; 2016; 2016():4918798. PubMed ID: 27891514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early cyst growth is associated with the increased nuclear expression of cyclin D1/Rb protein in an autosomal-recessive polycystic kidney disease rat model.
    Schwensen KG; Burgess JS; Graf NS; Alexander SI; Harris DC; Phillips JK; Rangan GK
    Nephron Exp Nephrol; 2011; 117(4):e93-103. PubMed ID: 20924203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
    Ma LJ; Marcantoni C; Linton MF; Fazio S; Fogo AB
    Kidney Int; 2001 May; 59(5):1899-910. PubMed ID: 11318962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis.
    Aoki Y; Maeno T; Aoyagi K; Ueno M; Aoki F; Aoki N; Nakagawa J; Sando Y; Shimizu Y; Suga T; Arai M; Kurabayashi M
    Respiration; 2009; 77(3):311-9. PubMed ID: 18974632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kidney cysts, pancreatic cysts, and biliary disease in a mouse model of autosomal recessive polycystic kidney disease.
    Williams SS; Cobo-Stark P; James LR; Somlo S; Igarashi P
    Pediatr Nephrol; 2008 May; 23(5):733-41. PubMed ID: 18286309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Long-Term Exercise on Liver Cyst in Polycystic Liver Disease Model Rats.
    Sato Y; Qiu J; Miura T; Kohzuki M; Ito O
    Med Sci Sports Exerc; 2020 Jun; 52(6):1272-1279. PubMed ID: 31880641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Src inhibition ameliorates polycystic kidney disease.
    Sweeney WE; von Vigier RO; Frost P; Avner ED
    J Am Soc Nephrol; 2008 Jul; 19(7):1331-41. PubMed ID: 18385429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.